This invention relates to the cardiovascular field. Specifically, it relates to the application of ANGPTL2
protein in the treatment and assessment of predicting
occlusion after coronary
artery bypass grafting (CABG). The biomarker of this invention can accurately target treatment and predict the risk of long-term
occlusion of the
venous graft after CABG.